Insights & Resources

J.P. Morgan's Q1 2025 biopharma and medtech reports reveal larger deals, global growth and financial strategies shaping the life sciences industry.

Download our white paper to learn how to even begin to measure and report GHG emissions.

J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.

The Q3 2024 Medtech Report from J.P. Morgan spotlights heightened investments, mergers and public offerings, signaling a positive industry outlook.

CEOs can leverage established ESG principles and best practices to create sustainable business operations and promote long-term growth.

The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.

As Local Law 97 mandates emission reductions for large buildings in NYC, property owners are taking proactive steps to ensure compliance and avoid fines.

The DOE has introduced a national definition of a zero emissions building, setting clear criteria for energy-efficient buildings to reduce greenhouse gas emissions.

Discover how the Inflation Reduction Act of 2022 boosts tax deductions for energy efficient commercial buildings with major incentives reaching up to $5 per sq. ft.

In a business sale, due diligence is critical to mitigate the risk of unexpected tax issues for buyers and sellers. Find out key components of tax due diligence.

Find out how innovative manufacturers can position themselves to leverage this new tariff on carbon and changing EU carbon regulations.